JP6959258B2 - 改変された腫瘍溶解性ウイルス - Google Patents

改変された腫瘍溶解性ウイルス Download PDF

Info

Publication number
JP6959258B2
JP6959258B2 JP2018555309A JP2018555309A JP6959258B2 JP 6959258 B2 JP6959258 B2 JP 6959258B2 JP 2018555309 A JP2018555309 A JP 2018555309A JP 2018555309 A JP2018555309 A JP 2018555309A JP 6959258 B2 JP6959258 B2 JP 6959258B2
Authority
JP
Japan
Prior art keywords
virus
tumor
inhibitors
gene
promoter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018555309A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019501670A (ja
JP2019501670A5 (enExample
Inventor
コフィン，ロバート
Original Assignee
レプリミュン リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57796748&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6959258(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1600382.4A external-priority patent/GB201600382D0/en
Priority claimed from GBGB1600380.8A external-priority patent/GB201600380D0/en
Priority claimed from GBGB1600381.6A external-priority patent/GB201600381D0/en
Application filed by レプリミュン リミテッド filed Critical レプリミュン リミテッド
Publication of JP2019501670A publication Critical patent/JP2019501670A/ja
Publication of JP2019501670A5 publication Critical patent/JP2019501670A5/ja
Priority to JP2021163811A priority Critical patent/JP7295192B2/ja
Publication of JP6959258B2 publication Critical patent/JP6959258B2/ja
Application granted granted Critical
Priority to JP2023094818A priority patent/JP2023113885A/ja
Priority to JP2025128636A priority patent/JP2025163138A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16621—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16633—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2018555309A 2016-01-08 2017-01-09 改変された腫瘍溶解性ウイルス Active JP6959258B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2021163811A JP7295192B2 (ja) 2016-01-08 2021-10-05 改変された腫瘍溶解性ウイルス
JP2023094818A JP2023113885A (ja) 2016-01-08 2023-06-08 改変された腫瘍溶解性ウイルス
JP2025128636A JP2025163138A (ja) 2016-01-08 2025-07-31 改変された腫瘍溶解性ウイルス

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB1600381.6A GB201600381D0 (en) 2016-01-08 2016-01-08 Virus strain
GB1600381.6 2016-01-08
GBGB1600380.8A GB201600380D0 (en) 2016-01-08 2016-01-08 Modified virus
GB1600382.4 2016-01-08
GB1600380.8 2016-01-08
GBGB1600382.4A GB201600382D0 (en) 2016-01-08 2016-01-08 Engineered virus
PCT/GB2017/050036 WO2017118864A1 (en) 2016-01-08 2017-01-09 Modified oncolytic viurs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021163811A Division JP7295192B2 (ja) 2016-01-08 2021-10-05 改変された腫瘍溶解性ウイルス

Publications (3)

Publication Number Publication Date
JP2019501670A JP2019501670A (ja) 2019-01-24
JP2019501670A5 JP2019501670A5 (enExample) 2020-01-30
JP6959258B2 true JP6959258B2 (ja) 2021-11-02

Family

ID=57796748

Family Applications (8)

Application Number Title Priority Date Filing Date
JP2018555309A Active JP6959258B2 (ja) 2016-01-08 2017-01-09 改変された腫瘍溶解性ウイルス
JP2018555310A Active JP7038065B2 (ja) 2016-01-08 2017-01-09 腫瘍溶解性ウイルス株
JP2018555311A Active JP7038664B2 (ja) 2016-01-08 2017-01-09 操作された腫瘍溶解性ウイルス
JP2021163811A Active JP7295192B2 (ja) 2016-01-08 2021-10-05 改変された腫瘍溶解性ウイルス
JP2022034569A Pending JP2022078225A (ja) 2016-01-08 2022-03-07 操作された腫瘍溶解性ウイルス
JP2023094818A Pending JP2023113885A (ja) 2016-01-08 2023-06-08 改変された腫瘍溶解性ウイルス
JP2024119344A Pending JP2024153748A (ja) 2016-01-08 2024-07-25 操作された腫瘍溶解性ウイルス
JP2025128636A Pending JP2025163138A (ja) 2016-01-08 2025-07-31 改変された腫瘍溶解性ウイルス

Family Applications After (7)

Application Number Title Priority Date Filing Date
JP2018555310A Active JP7038065B2 (ja) 2016-01-08 2017-01-09 腫瘍溶解性ウイルス株
JP2018555311A Active JP7038664B2 (ja) 2016-01-08 2017-01-09 操作された腫瘍溶解性ウイルス
JP2021163811A Active JP7295192B2 (ja) 2016-01-08 2021-10-05 改変された腫瘍溶解性ウイルス
JP2022034569A Pending JP2022078225A (ja) 2016-01-08 2022-03-07 操作された腫瘍溶解性ウイルス
JP2023094818A Pending JP2023113885A (ja) 2016-01-08 2023-06-08 改変された腫瘍溶解性ウイルス
JP2024119344A Pending JP2024153748A (ja) 2016-01-08 2024-07-25 操作された腫瘍溶解性ウイルス
JP2025128636A Pending JP2025163138A (ja) 2016-01-08 2025-07-31 改変された腫瘍溶解性ウイルス

Country Status (13)

Country Link
US (13) US10626377B2 (enExample)
EP (8) EP3400291B2 (enExample)
JP (8) JP6959258B2 (enExample)
KR (2) KR20250026348A (enExample)
CN (3) CN109415703B (enExample)
AU (2) AU2017205216B2 (enExample)
CA (3) CA3011009A1 (enExample)
DK (4) DK3805376T3 (enExample)
ES (4) ES2841300T5 (enExample)
IL (2) IL260480B (enExample)
MX (1) MX2018008413A (enExample)
SG (2) SG11201805835WA (enExample)
WO (4) WO2017118867A1 (enExample)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0107736A (pt) * 2000-01-21 2002-11-19 Biovex Ltd Uso de uma cepa de vìrus não laboratorial, métodos para determinar se um gene tem um efeito sobre um fenótipo associado com um distúrbio dos sistemas nervosos periférico e central ou sobre uma célula dos sistemas nervosos periférico e central, para determinar se um gene codifica um antìgeno associado com uma infecção patogênica ou câncer, para determinar a adequabilidade de uma cepa de vìrus não laboratorial para modificação em uma cepa modificada, para determinar se um gene aumenta os efeitos anti-tumorais de um vìrus e para produzir uma cepa de vìrus não laboratorial oncolìtica, modificada, cepa de vìrus não laboratorial, uso de um gene, cepa hsv1 js1, composição farmacêutica, e, métodos para tratar um tumor em um indivìduo, para suprir um gene a um indivìduo e para tratar ou impedir um distúrbio do sistemas nervosos periférico e central
HUE037460T2 (hu) 2005-12-02 2018-08-28 Icahn School Med Mount Sinai Nem-natív felületi fehérjéket prezentáló kiméra Newcastle disease vírusok és alkalmazásuk
US8901798B2 (en) 2007-05-31 2014-12-02 Regal Beloit America, Inc. Switched reluctance machines with minimum stator core
US20160015760A1 (en) 2013-03-14 2016-01-21 Icahn School Of Medicine At Mount Sinai Newcastle disease viruses and uses thereof
US20180133327A1 (en) 2015-03-16 2018-05-17 Amal Therapeutics Sa Cell Penetrating Peptides and Complexes Comprising the Same
JP7032311B2 (ja) 2015-07-16 2022-03-08 バイオエクセル セラピューティクス，インコーポレイテッド 免疫調節を使用してがんを処置するための新規手法
MX2018008413A (es) 2016-01-08 2019-02-20 Replimune Ltd Virus oncolitico modificado.
JP2019508063A (ja) 2016-01-27 2019-03-28 オンコラス， インコーポレイテッド 腫瘍溶解性ウイルスベクター及びその使用
CA3010779A1 (en) 2016-03-16 2017-09-21 Amal Therapeutics Sa Combination of an immune checkpoint modulator and a complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist for use in medicine
KR102323872B1 (ko) * 2016-04-22 2021-11-08 임비라 컴퍼니 리미티드 암치료용 종양 용해성 단순 헤르페스 바이러스(oHSV) 절대 벡터 및 그 구조체의 구조
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
US20190336552A1 (en) 2016-05-30 2019-11-07 Astellas Pharma Inc. Genetically engineered vaccinia viruses
US10888594B2 (en) 2016-05-30 2021-01-12 National University Corporation Tottori University Genetically engineered vaccinia viruses
RU2021127872A (ru) 2016-06-30 2021-11-09 Онкорус, Инк. Доставка терапевтических полипептидов посредством псевдотипированных онколитических вирусов
KR102879364B1 (ko) 2016-09-21 2025-11-04 아말 테라퓨틱스 에스에이 암 치료를 위한, 세포 투과 펩타이드, 멀티 에피토프 및 tlr 펩타이드 작용제를 포함하는 융합체
CN108261426B (zh) * 2017-01-04 2019-04-05 杭州康万达医药科技有限公司 药物组合物及其在治疗肿瘤和/或癌症的药物中的应用
GB201700350D0 (en) * 2017-01-09 2017-02-22 Replimune Ltd Altered virus
EP3615934A1 (en) 2017-04-28 2020-03-04 Merck Sharp & Dohme Corp. Biomarkers for cancer therapeutics
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
SG11202000691XA (en) 2017-07-26 2020-02-27 Oncorus Inc Oncolytic viral vectors and uses thereof
ES2975221T3 (es) 2017-08-03 2024-07-04 Amgen Inc Muteínas de interleucina-21 y métodos de tratamiento
CN116003405A (zh) 2017-09-08 2023-04-25 美国安进公司 Kras g12c的抑制剂及其使用方法
CN109554353B (zh) * 2017-09-26 2021-08-06 杭州康万达医药科技有限公司 分离的重组溶瘤痘病毒、药物组合物及其在治疗肿瘤和/或癌症的药物中的用途
WO2019093435A1 (ja) * 2017-11-08 2019-05-16 国立大学法人 鹿児島大学 安全を確保しながら転移性がんまで効果的に治療可能な、搭載する免疫誘導遺伝子の最適発現レベルを与える発現制御システムを有する腫瘍溶解性ウイルス（腫瘍溶解性免疫治療）
CA3082117A1 (en) * 2017-11-13 2019-05-16 Bioxcel Therapeutics, Inc. Methods and compositions for treating cancer by modifying multiple arms of the immune system
EP3731850A4 (en) 2017-12-29 2021-12-01 Oncorus, Inc. ONCOLYTIC VIRUS DELIVERY OF THERAPEUTIC POLYPEPTIDES
JOP20200172A1 (ar) 2018-01-12 2020-07-12 Amgen Inc الأجسام المضادة لـ pd-1 وطرق العلاج
WO2019147982A1 (en) * 2018-01-26 2019-08-01 Celldex Therapeutics, Inc. Methods of treating cancer with dendritic cell mobilizing agents
GB201804473D0 (en) * 2018-03-21 2018-05-02 Valo Therapeutics Oy Modified oncolytic adenoviruses
CN108635380A (zh) * 2018-04-13 2018-10-12 北京唯源立康生物科技有限公司 重组溶瘤病毒组合物及其在制备用于治疗肿瘤的药物中的应用
JP2021527694A (ja) * 2018-06-21 2021-10-14 レプリミュン リミテッド 腫瘍溶解性ウイルスを用いた処置
AU2019292580A1 (en) * 2018-06-29 2021-02-04 Krystal Biotech, Inc. Compositions and methods for antibody delivery
CN109161561A (zh) * 2018-08-09 2019-01-08 湖北科技学院 一种选择性杀灭前列腺癌细胞的新型溶瘤病毒及其构建方法
EP3837277A4 (en) 2018-08-17 2022-05-11 Icahn School of Medicine at Mount Sinai RECOMBINANT NEWCASTLE DISEASE VIRUSES AND THEIR USES IN THE PREVENTION OF RSV DISEASE OR HUMAN METAPNEUMOVIRUS INFECTION
CN119955743A (zh) * 2018-09-10 2025-05-09 上海锦斯生物技术有限公司 修饰的溶瘤病毒、其组合物和用途
TWI824020B (zh) 2018-09-26 2023-12-01 日商安斯泰來製藥股份有限公司 藉由腫瘤溶解性牛痘病毒與免疫檢查點抑制劑併用之癌症療法以及用於其之醫藥組合物及組合醫藥
EP3902529A1 (en) 2018-12-27 2021-11-03 Amgen Inc. Lyophilized virus formulations
CN111606999B (zh) * 2019-02-26 2022-09-06 南京惟亚德生物医药有限公司 兼具激活免疫共刺激信号通路和阻断免疫检查点的复制型溶瘤腺病毒及其应用
JP7679303B2 (ja) * 2019-03-05 2025-05-19 アムジエン・インコーポレーテツド がんを治療するための腫瘍溶解性ウイルスの使用
TW202102543A (zh) 2019-03-29 2021-01-16 美商安進公司 溶瘤病毒在癌症新輔助療法中之用途
CN110054678B (zh) * 2019-05-16 2023-04-18 中国医学科学院血液病医院（血液学研究所） 一种膜结合型mFLT3LG蛋白及其应用
CN110218707B (zh) * 2019-05-29 2021-10-22 上海市公共卫生临床中心 一种新型溶瘤病毒及其制备方法和应用
US20220273739A1 (en) * 2019-08-05 2022-09-01 National University Corporation Tokai National Higher Education And Research System Combination drug for treating malignant tumor, pharmaceutical composition for treating malignant tumor, and pharmaceutical composition for malignant tumor treatment
CA3156880A1 (en) * 2019-11-06 2021-05-14 Memgen, Inc. Replication-enhanced oncolytic adenoviruses
CN110982794B (zh) * 2020-03-05 2020-06-16 北京唯源立康生物科技有限公司 一种修饰的单纯疱疹病毒
CN110982795B (zh) * 2020-03-05 2020-06-16 北京唯源立康生物科技有限公司 一种单纯疱疹病毒及其用途
US20240216533A1 (en) * 2020-03-05 2024-07-04 Beijing Wellgene Company Ltd. Herpes simplex virus and use thereof
JPWO2021193081A1 (enExample) * 2020-03-23 2021-09-30
US20230355804A1 (en) 2020-06-29 2023-11-09 Flagship Pioneering Innovations V, Inc. Viruses engineered to promote thanotransmission and their use in treating cancer
US11839659B2 (en) 2020-07-02 2023-12-12 Northwestern University Proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of indoleamine 2,3-dioxygenase (IDO) protein
CN112941039A (zh) * 2021-02-01 2021-06-11 南京大学 一种新型类囊泡溶瘤病毒及其在制备抗肿瘤药物上的应用
DE102022104146A1 (de) 2021-03-19 2022-09-22 Yamada Manufacturing Co., Ltd. Lenkvorrichtung
IL307223A (en) * 2021-04-08 2023-11-01 Immvira Biopharmaceuticals Co Ltd Genetically modified oncolytic herpes simplex virus delivering chemokine and tumor associated/specific antigen
WO2022245808A1 (en) * 2021-05-18 2022-11-24 The Penn State Research Foundation Oncolytic virus based cancer therapy
CN113583979B (zh) * 2021-08-03 2022-11-22 杭州荣谷生物科技有限公司 一种重组溶瘤痘苗病毒、制备方法及其用途
US20250128337A1 (en) 2022-01-11 2025-04-24 Mitsubishi Materials Corporation Surface-coated cutting tool
WO2024055022A2 (en) * 2022-09-08 2024-03-14 Virogin Biotech Canada Ltd Oncolytic virus expressing an immune cell engager for tumor targeting
WO2025248110A1 (en) * 2024-05-31 2025-12-04 Replimune Limited An oncolytic herpes simplex virus (hsv) and an anti-pd-1 antibody for use in treating braf mutant melanoma
WO2026010067A1 (ko) * 2024-07-01 2026-01-08 주식회사 피비이뮨테라퓨틱스 길항성 항-cd40 인간화 항체

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU594014B2 (en) 1984-03-21 1990-03-01 Research Corporation Technologies, Inc. Recombinant DNA molecules
CA1282721C (en) 1984-06-04 1991-04-09 Bernard Roizman Herpes simplex virus as a vector
US5288641A (en) 1984-06-04 1994-02-22 Arch Development Corporation Herpes Simplex virus as a vector
DE3584341D1 (de) 1984-08-24 1991-11-14 Upjohn Co Rekombinante dna-verbindungen und expression von polypeptiden wie tpa.
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5698531A (en) 1989-03-31 1997-12-16 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5328688A (en) 1990-09-10 1994-07-12 Arch Development Corporation Recombinant herpes simplex viruses vaccines and methods
US6770274B1 (en) 1990-09-14 2004-08-03 The General Hospital Corporation Viral mutant HSV mediated destruction of neoplastic cells
US6040169A (en) 1991-01-31 2000-03-21 Medical Research Council Herpes simplex virus-1 deletion variants and vaccines thereof
ES2183811T3 (es) 1992-03-31 2003-04-01 Arch Dev Corp Tratamiento de enfermedades tumorigenas con un hsv modificado.
US6699468B1 (en) 1994-06-23 2004-03-02 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
JPH11513390A (ja) 1995-10-06 1999-11-16 アーチ デベロップメント コーポレイション 細胞殺傷のウイルス増強のための方法および組成物
US5824318A (en) 1996-07-24 1998-10-20 American Cyanamid Company Avirulent herpetic viruses useful as tumoricidal agents and vaccines
GB9700411D0 (en) 1997-01-10 1997-02-26 Univ London Eukaryotic gene expression cassette and uses thereof
US6379674B1 (en) 1997-08-12 2002-04-30 Georgetown University Use of herpes vectors for tumor therapy
US7300774B1 (en) 1999-12-09 2007-11-27 The Regents Of The University Of California Multimeric fusion proteins of the TNF superfamily ligands
US6428968B1 (en) 1999-03-15 2002-08-06 The Trustees Of The University Of Pennsylvania Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
MXPA02004736A (es) 1999-11-12 2003-01-28 Oncolytics Biotech Inc Virus para el tratamiento de trastornos proliferativos celulares.
BR0107736A (pt) 2000-01-21 2002-11-19 Biovex Ltd Uso de uma cepa de vìrus não laboratorial, métodos para determinar se um gene tem um efeito sobre um fenótipo associado com um distúrbio dos sistemas nervosos periférico e central ou sobre uma célula dos sistemas nervosos periférico e central, para determinar se um gene codifica um antìgeno associado com uma infecção patogênica ou câncer, para determinar a adequabilidade de uma cepa de vìrus não laboratorial para modificação em uma cepa modificada, para determinar se um gene aumenta os efeitos anti-tumorais de um vìrus e para produzir uma cepa de vìrus não laboratorial oncolìtica, modificada, cepa de vìrus não laboratorial, uso de um gene, cepa hsv1 js1, composição farmacêutica, e, métodos para tratar um tumor em um indivìduo, para suprir um gene a um indivìduo e para tratar ou impedir um distúrbio do sistemas nervosos periférico e central
US7749745B2 (en) 2001-03-27 2010-07-06 Georgetown University Viral vectors and their use in therapeutic methods
GB0317511D0 (en) * 2003-07-25 2003-08-27 Biovex Ltd Viral vectors
WO2006002394A2 (en) 2004-06-24 2006-01-05 New York University Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response
CA2586844A1 (en) 2004-11-04 2006-05-11 Pfizer Products Inc. Ctla-4 antibody and aromatase inhibitor or combination treatment for breast cancer
US9866961B2 (en) 2004-12-01 2018-01-09 Todd Beauchamp Multi-channel loudspeaker enclosure with laterally projecting wings and method for orienting and driving multiple loudspeakers
TW200719913A (en) 2005-03-08 2007-06-01 Pharmacia & Upjohn Co Llc Anti-madcam antibody compositions
SI2650020T1 (sl) 2005-05-06 2017-03-31 Providence Health & Services - Oregon Technology Transfer Trimerični OX40 imunoglobulinski fuzijski protein in postopek za njegovo uporabo
EP1909849B1 (en) 2005-06-23 2013-08-07 The University Of Houston Use of mutant herpes simplex virus-2 for cancer therapy
GB0522476D0 (en) 2005-11-03 2005-12-14 Biovex Ltd Oncolytic herpes virus vectors
JP6092497B2 (ja) 2006-03-30 2017-03-08 ユニバーシティー オブ カリフォルニア 抗ｃｔｌａ−４抗体の限局性分泌のための方法および組成物
US8313896B2 (en) * 2008-04-04 2012-11-20 The General Hospital Corporation Oncolytic herpes simplex virus immunotherapy in the treatment of brain cancer
WO2009148488A2 (en) 2008-05-29 2009-12-10 The General Hospital Corporation Use of oncolytic herpes viruses for killing cancer stem cells
EP2356219A4 (en) 2008-10-08 2017-07-05 Intrexon Corporation Engineered cells expressing multiple immunomodulators and uses thereof
US20100297072A1 (en) 2009-05-19 2010-11-25 Depinho Ronald A Combinations of Immunostimulatory Agents, Oncolytic Virus, and Additional Anticancer Therapy
WO2011063309A1 (en) 2009-11-20 2011-05-26 Infinity Pharmaceuticals, Inc. Methods and compositions for treating hedgehog-associated cancers
WO2011119925A2 (en) * 2010-03-25 2011-09-29 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Synthetic herpes simplex viruses for treatment of cancers
WO2011118866A1 (ko) 2010-03-26 2011-09-29 연세대학교 산학협력단 네트워크를 통한 심사요청 방법
KR20130108371A (ko) * 2010-09-24 2013-10-02 온코스 테라퓨틱스 오와이 단클론 항―ｃｔｌａ－４ 항체를 암호화하는 종양분해 아데노바이러스 벡터
ES2704632T3 (es) * 2011-09-08 2019-03-19 Univ New York Virus de herpes simplex oncolítico y sus usos terapéuticos
FI20115914L (fi) 2011-09-16 2013-03-17 Oncos Therapeutics Ltd Muunnettu onkolyyttinen virus
CN104427992B (zh) * 2012-01-25 2017-12-19 德那翠丝有限公司 生物标志物及使用溶瘤病毒和免疫调节剂的组合疗法
KR20170039774A (ko) 2012-07-30 2017-04-11 알렉스 와 힌 영 종양 세포, 암세포파괴 바이러스 벡터 및 면역 체크포인트 조절인자를 갖는 암 백신 시스템
AU2013308595C1 (en) 2012-08-30 2019-01-17 Amgen Inc. A method for treating melanoma using a herpes simplex virus and an immune checkpoint inhibitor
HK1213924A1 (zh) 2012-10-23 2016-07-15 Bristol-Myers Squibb Company 用於治療癌症的抗kir和抗ctla-4抗體組合
KR20150118159A (ko) 2013-02-22 2015-10-21 에프. 호프만-라 로슈 아게 암의 치료 방법 및 약물 내성의 예방 방법
US20160015760A1 (en) 2013-03-14 2016-01-21 Icahn School Of Medicine At Mount Sinai Newcastle disease viruses and uses thereof
EA202191926A3 (ru) 2013-09-03 2022-01-31 Медиммун Лимитед Композиции, содержащие аттенуированный вирус ньюкаслской болезни, и способы применения для лечения неоплазии
KR102272932B1 (ko) 2013-10-25 2021-07-05 싸이오서스 테라퓨틱스 엘티디. 이종 유전자로 무장된 종양살상 아데노바이러스
EP3063279B1 (en) 2013-10-28 2020-01-01 University of Pittsburgh - Of the Commonwealth System of Higher Education Oncolytic hsv vector
AU2014352749A1 (en) 2013-11-22 2016-06-09 Dnatrix, Inc. Adenovirus expressing immune cell stimulatory receptor agonist(s)
WO2015128313A1 (en) 2014-02-25 2015-09-03 Deutsches Krebsforschungszentrum Rna viruses for immunovirotherapy
MA39818A (fr) * 2014-03-30 2017-02-08 Benevir Biopharm Inc Virus oncolytiques « armés » comprenant un inhibiteur de tap exogène et leurs utilisations thérapeutiques
JP6895374B2 (ja) 2014-07-16 2021-06-30 トランジェーヌＴｒａｎｓｇｅｎｅ 免疫チェックポイントモジュレーターの発現用腫瘍溶解性ウイルス
KR102504758B1 (ko) 2014-07-16 2023-02-28 트랜스진 종양 세포 붕괴성 바이러스와 면역 체크포인트 조절제의 배합물
US20160040186A1 (en) 2014-08-07 2016-02-11 Xiaoyun Liu Dna construct and method for transgene expression
GB201419579D0 (en) 2014-11-03 2014-12-17 Iomet Pharma Ltd Pharmaceutical compound
EP3247672B1 (en) 2015-01-23 2018-11-28 Dreamwell, Ltd. Automated mattress manufacturing process and apparatus
MX2018008413A (es) * 2016-01-08 2019-02-20 Replimune Ltd Virus oncolitico modificado.
KR102323872B1 (ko) 2016-04-22 2021-11-08 임비라 컴퍼니 리미티드 암치료용 종양 용해성 단순 헤르페스 바이러스(oHSV) 절대 벡터 및 그 구조체의 구조
GB201700350D0 (en) 2017-01-09 2017-02-22 Replimune Ltd Altered virus
US12029647B2 (en) * 2017-03-07 2024-07-09 4C Medical Technologies, Inc. Systems, methods and devices for prosthetic heart valve with single valve leaflet
JP2021527694A (ja) 2018-06-21 2021-10-14 レプリミュン リミテッド 腫瘍溶解性ウイルスを用いた処置
WO2020124274A1 (en) 2018-12-21 2020-06-25 Ottawa Hospital Research Institute Modified orthopoxvirus vectors

Also Published As

Publication number Publication date
US12458696B2 (en) 2025-11-04
EP3778881A1 (en) 2021-02-17
JP2019501670A (ja) 2019-01-24
WO2017118865A1 (en) 2017-07-13
US10626377B2 (en) 2020-04-21
US10612005B2 (en) 2020-04-07
US20190015466A1 (en) 2019-01-17
EP4628577A2 (en) 2025-10-08
US12024724B2 (en) 2024-07-02
JP7038065B2 (ja) 2022-03-17
WO2017118864A1 (en) 2017-07-13
JP2022002531A (ja) 2022-01-11
EP4219696A2 (en) 2023-08-02
US20250352646A1 (en) 2025-11-20
EP3400291A1 (en) 2018-11-14
KR20250026348A (ko) 2025-02-25
JP7295192B2 (ja) 2023-06-20
ES2841300T5 (es) 2024-08-06
DK3400291T3 (da) 2020-11-30
US10947513B2 (en) 2021-03-16
US20210254019A1 (en) 2021-08-19
HK1257224A1 (en) 2019-10-18
CN109312309A (zh) 2019-02-05
IL282985A (en) 2021-06-30
KR20180103956A (ko) 2018-09-19
ES2831080T3 (es) 2021-06-07
EP3805376B1 (en) 2025-08-06
US20240301365A1 (en) 2024-09-12
JP2024153748A (ja) 2024-10-29
ES3041885T3 (en) 2025-11-17
WO2017118866A1 (en) 2017-07-13
JP2019500909A (ja) 2019-01-17
DK3400290T3 (da) 2023-05-01
CN109415703B (zh) 2024-08-30
IL260480B (en) 2021-05-31
US20200199542A1 (en) 2020-06-25
EP3400291B2 (en) 2024-02-28
EP3400291B1 (en) 2020-11-04
JP7038664B2 (ja) 2022-03-18
JP2025163138A (ja) 2025-10-28
AU2022279486B2 (en) 2025-07-31
CN109153977B (zh) 2022-11-01
US12397053B2 (en) 2025-08-26
ES2943150T3 (es) 2023-06-09
US20190040366A1 (en) 2019-02-07
US20230212531A1 (en) 2023-07-06
JP2019501671A (ja) 2019-01-24
DK3400293T3 (da) 2020-10-19
US11427810B2 (en) 2022-08-30
EP3400292B1 (en) 2020-08-26
WO2017118867A1 (en) 2017-07-13
CA3011004A1 (en) 2017-07-13
US20240018488A1 (en) 2024-01-18
EP4219696A3 (en) 2023-09-27
US12049647B2 (en) 2024-07-30
EP3400293B2 (en) 2023-07-12
DK3400291T4 (da) 2024-04-02
ES2841300T3 (es) 2021-07-08
US11473063B2 (en) 2022-10-18
EP3400293A1 (en) 2018-11-14
AU2017205216B2 (en) 2022-11-24
US20190022157A1 (en) 2019-01-24
CN109312309B (zh) 2024-04-02
US20200208122A1 (en) 2020-07-02
US20190032024A1 (en) 2019-01-31
DK3400293T4 (da) 2023-08-28
US12465639B2 (en) 2025-11-11
EP3400290B1 (en) 2023-04-05
BR112018013930A2 (pt) 2018-12-11
US20230130992A1 (en) 2023-04-27
DK3400290T5 (da) 2024-09-23
EP3400290A1 (en) 2018-11-14
HK1257480A1 (en) 2019-10-18
MX2018008413A (es) 2019-02-20
KR102762431B1 (ko) 2025-02-03
EP3805376A1 (en) 2021-04-14
ES2831080T5 (es) 2023-10-30
SG11201805835WA (en) 2018-08-30
AU2022279486A1 (en) 2023-02-02
JP2023113885A (ja) 2023-08-16
IL282985B (en) 2022-04-01
EP3400293B1 (en) 2020-09-16
CN109415703A (zh) 2019-03-01
CA3010987A1 (en) 2017-07-13
AU2017205216A1 (en) 2018-08-09
JP2022078225A (ja) 2022-05-24
EP3400292A1 (en) 2018-11-14
US10570377B2 (en) 2020-02-25
CA3011009A1 (en) 2017-07-13
SG10202108724YA (en) 2021-09-29
US20230203453A1 (en) 2023-06-29
DK3805376T3 (da) 2025-09-29
HK1257074A1 (en) 2019-10-11
CN109153977A (zh) 2019-01-04

Similar Documents

Publication Publication Date Title
JP7295192B2 (ja) 改変された腫瘍溶解性ウイルス
JP2021527694A (ja) 腫瘍溶解性ウイルスを用いた処置
HK40045432A (en) Modified oncolytic virus
HK1257224B (en) Modified oncolytic virus

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20190606

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190606

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191212

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191212

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20201118

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201208

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210301

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210330

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210518

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210907

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211007

R150 Certificate of patent or registration of utility model

Ref document number: 6959258

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250